Quick Answer
BIOMARIN PHARMACEUTICAL INC reported Total Revenue of $3.22 billion for fiscal year 2025.
BIOMARIN PHARMACEUTICAL INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $3.22B +12.9% |
$2.85B +18.0% |
$2.42B +15.4% |
$2.10B +13.5% |
$1.85B -0.8% |
$1.86B +9.2% |
| Revenue (ASC 606) | $3.22B +12.9% |
$2.85B +18.0% |
$2.42B +15.4% |
$2.10B +13.5% |
$1.85B -0.8% |
$1.86B +9.2% |
| Net Income | $348.90M -18.3% |
$426.86M +154.6% |
$167.65M +18.4% |
$141.56M +320.9% |
-$64.08M -107.5% |
$854.03M +3681.1% |
| Diluted EPS | $1.80 -18.6% |
$2.21 +154.0% |
$0.87 +16.0% |
$0.75 +314.3% |
-$0.35 -107.8% |
$4.50 +3561.5% |
| Total Assets | $7.59B +8.7% |
$6.99B +2.2% |
$6.84B +7.3% |
$6.38B +6.2% |
$6.00B +2.7% |
$5.85B +24.7% |
| Cash and Equivalents | $1.31B +39.1% |
$942.84M +24.9% |
$755.13M +4.2% |
$724.53M +23.4% |
$587.28M -9.5% |
$649.16M +48.4% |
| Stockholders Equity | $6.09B +7.6% |
$5.66B +14.3% |
$4.95B +7.6% |
$4.60B +7.9% |
$4.27B +4.0% |
$4.10B +31.3% |
| R&D Expense | $921.93M +23.4% |
$747.18M +0.1% |
$746.77M +15.0% |
$649.61M +3.3% |
$628.79M +0.1% |
$628.12M -12.2% |
| Operating Income | $409.48M -15.4% |
$484.21M +160.6% |
$185.77M +15.4% |
$160.97M +295.5% |
-$82.34M -89.6% |
-$43.44M +56.8% |
| Shares Outstanding | 192.30M +0.8% |
190.76M +1.1% |
188.60M +1.3% |
186.25M +1.3% |
183.91M +1.2% |
181.74M +1.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $776.13M | +4.1% | -6.0% |
| Revenue (ASC 606) | September 30, 2025 | $776.13M | +4.1% | -6.0% |
| Net Income | September 30, 2025 | -$30.74M | -129.0% | -112.8% |
| Diluted EPS | September 30, 2025 | -$0.16 | -129.1% | -113.0% |
| Total Assets | September 30, 2025 | $7.61B | +11.1% | +2.1% |
| Cash and Equivalents | September 30, 2025 | $1.25B | +85.1% | +3.0% |
| Stockholders Equity | September 30, 2025 | $6.06B | +11.9% | +0.5% |
| R&D Expense | September 30, 2025 | $409.48M | +121.5% | +153.8% |
| Operating Income | September 30, 2025 | -$46.69M | -141.0% | -116.9% |
| Shares Outstanding | September 30, 2025 | 192.10M | +0.8% | +0.1% |
- BIOMARIN PHARMACEUTICAL INC reported Total Revenue of $3.22 billion for fiscal year 2025.
- BIOMARIN PHARMACEUTICAL INC showed an increase of +12.9% in Total Revenue compared to the prior fiscal year.
- BIOMARIN PHARMACEUTICAL INC reported Revenue (ASC 606) of $3.22 billion for fiscal year 2025.
- BIOMARIN PHARMACEUTICAL INC showed an increase of +12.9% in Revenue (ASC 606) compared to the prior fiscal year.
- BIOMARIN PHARMACEUTICAL INC reported Net Income of $348.90 million for fiscal year 2025.
- BIOMARIN PHARMACEUTICAL INC showed a decrease of -18.3% in Net Income compared to the prior fiscal year.
- BIOMARIN PHARMACEUTICAL INC reported Diluted EPS of $1.80 per share for fiscal year 2025.
- BIOMARIN PHARMACEUTICAL INC showed a decrease of -18.6% in Diluted EPS compared to the prior fiscal year.
- BIOMARIN PHARMACEUTICAL INC reported Total Assets of $7.59 billion for fiscal year 2025.
- BIOMARIN PHARMACEUTICAL INC showed an increase of +8.7% in Total Assets compared to the prior fiscal year.
- BIOMARIN PHARMACEUTICAL INC reported Cash and Equivalents of $1.31 billion for fiscal year 2025.
- BIOMARIN PHARMACEUTICAL INC showed an increase of +39.1% in Cash and Equivalents compared to the prior fiscal year.
- BIOMARIN PHARMACEUTICAL INC reported Stockholders Equity of $6.09 billion for fiscal year 2025.
- BIOMARIN PHARMACEUTICAL INC showed an increase of +7.6% in Stockholders Equity compared to the prior fiscal year.
- BIOMARIN PHARMACEUTICAL INC reported R&D Expense of $921.93 million for fiscal year 2025.
- BIOMARIN PHARMACEUTICAL INC showed an increase of +23.4% in R&D Expense compared to the prior fiscal year.
- BIOMARIN PHARMACEUTICAL INC reported Operating Income of $409.48 million for fiscal year 2025.
- BIOMARIN PHARMACEUTICAL INC showed a decrease of -15.4% in Operating Income compared to the prior fiscal year.
- BIOMARIN PHARMACEUTICAL INC reported Shares Outstanding of 192.30 million shares for fiscal year 2025.
- BIOMARIN PHARMACEUTICAL INC showed an increase of +0.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: